<DOC>
	<DOCNO>NCT02435147</DOCNO>
	<brief_summary>The purpose study validate long-term benefit denosumab osteoporosis treatment real-world clinical practice set . We hypothesize continued therapy ( 36+months ) denosumab increase trabecular bone score ( TBS ) femur strength index ( FSI ) reduce fracture bone health risk among post-menopausal woman osteoporosis .</brief_summary>
	<brief_title>Longitudinal Effects Denosumab Trabecular Bone Score Femur Strength Index</brief_title>
	<detailed_description>Bone fracture major cause morbidity health care expense among patient osteoporosis.The goal osteoporosis therapy reduce fracture risk . The administration denosumab 60 mg subcutaneously ( SC ) every six month show limit bone turnover , increase bone mineral density ( BMD ) , reduce risk new vertebral , non-vertebral , hip fracture among postmenopausal woman osteoporosis ( Cummings , 2009 ) . Although BMD important factor fracture risk , describe bone microarchitecture , relate bone quality mechanical bone strength . Trabecular bone score ( TBS ) index bone microarchitecture extract anterior-posterior spine dual-energy X-ray absorptiometry ( DXA ) . Previous research show TBS differentiate woman without fracture well predict future fracture even adjustment BMD ( Simonelli , Leib , Winzenrieth , &amp; Hans , 2012 ) . In study 29,407 Canadian woman age 50 year old time baseline hip spine DXA , health service record assess determine incidence non-traumatic osteoporotic fracture subsequent BMD testing . Lumbar spine TBS derive DXA examination blind clinical parameter outcomes . Osteoporotic fracture identify 1668 ( 5.7 % ) woman , include 439 ( 1.5 % ) spine 293 ( 1.0 % ) hip fracture . Significantly low spine TBS BMD find woman major osteoporotic , spine , hip fracture ( p &lt; 0.0001 ) . The result study suggest spine TBS predictive osteoporotic fracture provide additional clinical information independent spine hip BMD ; therefore , combine TBS trabecular texture index BMD incrementally improve fracture prediction postmenopausal woman ( Hans , Goertzen , Krieg , &amp; Leslie , 2011 ) . Clinical research demonstrate positive effect denosumab TBS time . In randomized , double-blind , placebo-controlled trial 215 postmenopausal woman low BMD spine total hip , denosumab ( 60mg SC every 6 month ) find increase lumbar spine QCT , DXA , TBS 12 month compare placebo alendronate ( Thomas , 2013 ) . In another study conduct McClung et al , postmenopausal woman osteoporosis receive denosumab find significant increase TBS , independent BMD , 36 month compare baseline placebo ( McClung , Lippuner , Brandi , Kaufman , Zanchetta , &amp; Krieg , 2012 ) . Femur strength index ( FSI ) , measure femoral bone density , structure , strength , also show predict hip fracture independent bone density hip axis length . In study compare FSI group woman age 50 year old without hip fracture ( 365 prior hip fracture 2,141 control ) , FSI find significantly low fracture group , adjust T score hip axis length ( Faulkner , et al. , 2006 ) . Like TBS , FSI obtain femur DXA measurement use modern software . This single-site , open-label , non-randomized , observational study design assess change TBS FSI 36 month . among post-menopausal woman osteoporosis take denosumab . All patient include study medical care principal investigator . Subjects enter study complete 36 month treatment denosumab evaluable DXA scan . Medical record retrospectively review percent change TBS FSI score calculate .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion eligible study entry : Postmenopausal female diagnose osteoporosis Age 4090 year Completed 36 month denosumab therapy ( SQ ; 60mg every 6 month ) yet receive 42 month injection Availability DXA scan studyrequired time point , include willingness subject undergo DXA evaluation 36 month , require Provided write informed consent Patients exclude study follow reason : Received denosumab injection less 36 month Patients miss 1 dose denosumab 36 month period Contraindicated treatment denosumab History rheumatoid arthritis Current diagnosis hyperparathyroidism ; hyperthyroidism ; osteomalacia , know disease affect bone In opinion investigator , kind disorder may compromise ability subject provide write informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>